A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects
A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects
Sponsor: argenx
A PHASE1 clinical study on Bioavailability Study, this trial is completed. The trial is conducted by argenx and has accumulated 9 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Aug 2019 — Sep 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Aug 2018 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- argenx
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Groningen, Netherlands